(AGENPARL) – gio 27 aprile 2023 27 April 2023 FOR IMMEDIATE RELEASE Pfizer AGM: COVID-19 meds brought in nearly $1,500…
Browsing: COVID-19
(AGENPARL) – LONDON gio 27 aprile 2023 Understanding the impact of repeat routine lateral flow device (LFD) testing of asymptomatic…
(AGENPARL) – LONDON gio 27 aprile 2023 A summary of the historic processes, frameworks and governance across UKHSA ensuring the…
[lid] – Il Giappone ha deciso formalmente giovedì di declassare lo status legale del nuovo coronavirus a un livello pari…
(AGENPARL) – mer 26 aprile 2023 [Auditor General Manitoba] news release April 26, 2023 Manitoba effectively managed COVID-19 vaccine rollout,…
(AGENPARL) mar 25 aprile 2023 In 2022, over 8.2 thousand people died of COVID-19. This represents a sharp decline on…
(AGENPARL) – NEW HAVEN, CONNECTICUT (USA) mar 25 aprile 2023 A Yale clinician answers questions about the FDA’s authorization of an…
(AGENPARL) – SILVER SPRING lun 24 aprile 2023 FDA authorized bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for…
(AGENPARL) – SILVER SPRING ven 21 aprile 2023 Supporting regulatory flexibility for imports related to the COVID-19 pandemic Fonte/Source: http://www.fda.gov/drugs/coronavirus-covid-19-drugs/import-drugs-potential-covid-19-treatment
(AGENPARL) – ven 21 aprile 2023 Data di pubblicazione: 21/04/2023 Fonte/Source: https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=6230